For UK pharmaceutical and life sciences leaders
NICE approved your medicine two years ago and patients still haven't heard of it
UK regulations permit disease awareness and patient advocacy activity, yet most pharma companies leave both entirely to chance. The result is slow uptake, frustrated HCPs, and patients who never ask the right question.
Two minutes. Solva follows up with specific patient engagement options.
- Low patient-initiated inquiries about new treatments
- Patients presenting late with advanced disease due to lack of awareness
- Suboptimal uptake of NICE-approved specialty medicines despite clinical need
- Patient advocacy groups feeling disengaged or unheard by pharmaceutical companies
- Inefficient patient recruitment for clinical trials
- Delayed market access and slower uptake of innovative therapies
- Suboptimal revenue generation from specialty medicines
- Increased marketing spend on HCPs with diminishing returns
- Delayed diagnosis and treatment initiation for eligible patients
- Poorer patient outcomes due to lack of adherence or appropriate therapy
- Perception of being solely profit-driven, neglecting patient needs
- Negative sentiment from patient advocacy groups and the wider public
Trials incorporating ongoing patient engagement achieve 28-41% higher completion rates compared to traditional approaches (Nclusiv, 2025)
Source: https://nclusiv.co.uk/blog/f/patient-engagement-statistics-data-that-proves-impact
Frequently asked questions
Why does this problem persist?
UK pharma regulations restrict direct-to-consumer advertising, but patient advocacy and disease awareness are permitted and underutilised. Many pharma companies focus entirely on HCP engagement and neglect the patient pathway - meaning eligible patients are not asking their GP or consultant about treatment options.
What is the cost of leaving it unaddressed?
Every £1 invested in patient engagement returns £3-5 in cost savings and efficiency gains (Nclusiv, 2025)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.